Purple Biotech Statistics

Total Valuation

Purple Biotech has a market cap or net worth of $6.28 million. The enterprise value is -$3.83 million.

Market Cap	6.28M
Enterprise Value	-3.83M

Important Dates

The next estimated earnings date is Wednesday, May 20, 2026, before market open.

Earnings Date	May 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Purple Biotech has 1.86 billion shares outstanding. The number of shares has increased by 192.79% in one year.

Current Share Class	n/a
Shares Outstanding	1.86B
Shares Change (YoY)	+192.79%
Shares Change (QoQ)	+161.42%
Owned by Insiders (%)	0.94%
Owned by Institutions (%)	19.63%
Float	1.84B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.65
P/TBV Ratio	2.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.03.

Current Ratio	1.27
Quick Ratio	1.23
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -124.46% and return on invested capital (ROIC) is -20.28%.

Return on Equity (ROE)	-124.46%
Return on Assets (ROA)	-15.97%
Return on Invested Capital (ROIC)	-20.28%
Return on Capital Employed (ROCE)	-71.05%
Weighted Average Cost of Capital (WACC)	0.39%
Revenue Per Employee	n/a
Profits Per Employee	-$2.64M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -83.17% in the last 52 weeks. The beta is -0.70, so Purple Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.70
52-Week Price Change	-83.17%
50-Day Moving Average	4.43
200-Day Moving Average	9.14
Relative Strength Index (RSI)	52.40
Average Volume (20 Days)	14,050

Short Selling Information

The latest short interest is 7,972, so 0.86% of the outstanding shares have been sold short.

Short Interest	7,972
Short Previous Month	9,933
Short % of Shares Out	0.86%
Short % of Float	n/a
Short Ratio (days to cover)	0.75

Income Statement

Revenue	n/a
Gross Profit	-59,000
Operating Income	-6.98M
Pretax Income	-26.49M
Net Income	-26.39M
EBITDA	-6.97M
EBIT	-6.98M
Earnings Per Share (EPS)	-$0.03

Full Income Statement

Balance Sheet

The company has $9.57 million in cash and $244,000 in debt, giving a net cash position of $9.33 million or $0.01 per share.

Cash & Cash Equivalents	9.57M
Total Debt	244,000
Net Cash	9.33M
Net Cash Per Share	$0.01
Equity (Book Value)	9.66M
Book Value Per Share	0.01
Working Capital	2.11M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$5.66 million and capital expenditures -$3,000, giving a free cash flow of -$5.66 million.

Operating Cash Flow	-5.66M
Capital Expenditures	-3,000
Depreciation & Amortization	3,000
Net Borrowing	-217,000
Free Cash Flow	-5.66M
FCF Per Share	-$0.00

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Purple Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-192.79%
Shareholder Yield	-192.79%
Earnings Yield	-419.91%
FCF Yield	-90.06%

Analyst Forecast

The average price target for Purple Biotech is $30.00, which is 560.30% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$30.00
Price Target Difference	560.30%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on March 2, 2026. It was a reverse split with a ratio of 1:10.

Last Split Date	Mar 2, 2026
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	1